Robeco Institutional Asset Management B.V. Amgen Inc Transaction History

Robeco Institutional Asset Management B.V.

$66.7 Billion
Q3 2025

A detailed history of Robeco Institutional Asset Management B.V. transactions in Amgen Inc stock. As of the latest transaction made, Robeco Institutional Asset Management B.V. holds 437,569 shares of AMGN stock, worth $132 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares

437,569

Previous 444,152 1.48%

Holding current value

$132 Million

Previous $124 Million 0.43%

% of portfolio

0.19%

Previous 0.21%

45 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 22, 2025	SELL	$271.18 - $309.22 $1.79 Million - $2.04 Million	-6,583 Reduced 1.48%	437,569 $123 Million
Q2 2025 Jul 18, 2025	SELL	$262.28 - $309.85 $4.92 Million - $5.81 Million	-18,753 Reduced 4.05%	444,152 $124 Million
Q1 2025 Apr 23, 2025	BUY	$258.59 - $327.36 $11.3 Million - $14.3 Million	43,727 Added 10.43%	462,905 $144 Million
Q4 2024 Jan 22, 2025	SELL	$258.78 - $328.31 $9.43 Million - $12 Million	-36,427 Reduced 8.0%	419,178 $109 Million
Q3 2024 Oct 29, 2024	SELL	$309.38 - $337.38 $13.5 Million - $14.7 Million	-43,673 Reduced 8.75%	455,605 $147 Million
Q2 2024 Jul 22, 2024	SELL	$262.75 - $319.31 $132 Million - $160 Million	-501,070 Reduced 50.09%	499,278 $156 Million
Q1 2024 Apr 24, 2024	SELL	$268.87 - $324.56 $21.8 Million - $26.3 Million	-81,051 Reduced 7.5%	1,000,348 $284 Million
Q4 2023 Feb 14, 2024	BUY	$255.7 - $288.46 $90.1 Million - $102 Million	352,185 Added 48.3%	1,081,399 $311 Million
Q4 2023 Feb 08, 2024	SELL	$255.7 - $288.46 $69.7 Million - $78.6 Million	-272,540 Reduced 27.21%	729,214 $1.08 Billion
Q3 2023 Oct 23, 2023	SELL	$218.65 - $271.46 $14.8 Million - $18.4 Million	-67,810 Reduced 6.34%	1,001,754 $269 Million
Q2 2023 Jul 24, 2023	SELL	$214.27 - $253.37 $28.4 Million - $33.5 Million	-132,354 Reduced 11.01%	1,069,564 $237 Million
Q1 2023 May 03, 2023	BUY	$225.79 - $275.2 $11.5 Million - $14 Million	51,031 Added 4.43%	1,201,918 $291 Million
Q4 2022 Feb 06, 2023	SELL	$229.03 - $291.01 $11.6 Million - $14.8 Million	-50,768 Reduced 4.22%	1,150,887 $302 Million
Q3 2022 Dec 01, 2022	BUY	$224.46 - $253.15 $124 Million - $139 Million	550,439 Added 84.52%	1,201,655 $271 Million
Q3 2022 Oct 26, 2022	BUY	$224.46 - $253.15 $124 Million - $139 Million	550,439 Added 84.52%	1,201,655 $271 Million
Q2 2022 Dec 01, 2022	BUY	$230.71 - $256.74 $12.5 Million - $13.9 Million	54,144 Added 9.07%	651,216 $158 Million
Q2 2022 Jul 27, 2022	BUY	$230.71 - $256.74 $12.5 Million - $13.9 Million	54,144 Added 9.07%	651,216 $158 Million
Q1 2022 Dec 01, 2022	SELL	$219.27 - $242.57 $2.32 Million - $2.57 Million	-10,600 Reduced 1.74%	597,072 $144 Million
Q1 2022 Apr 26, 2022	SELL	$219.27 - $242.57 $2.32 Million - $2.57 Million	-10,600 Reduced 1.74%	597,072 $144 Million
Q4 2021 Dec 01, 2022	SELL	$198.88 - $227.6 $10.7 Million - $12.2 Million	-53,733 Reduced 8.12%	607,672 $137 Million
Q4 2021 Jan 31, 2022	SELL	$198.88 - $227.6 $10.7 Million - $12.2 Million	-53,733 Reduced 8.12%	607,672 $137 Million
Q3 2021 Dec 01, 2022	SELL	$212.27 - $248.7 $4.27 Million - $5.01 Million	-20,131 Reduced 2.95%	661,405 $141 Million
Q3 2021 Oct 20, 2021	SELL	$212.27 - $248.7 $4.27 Million - $5.01 Million	-20,131 Reduced 2.95%	661,405 $141 Million
Q2 2021 Dec 01, 2022	BUY	$233.58 - $259.14 $776,186 - $861,122	3,323 Added 0.49%	681,536 $166 Million
Q2 2021 Jul 28, 2021	BUY	$233.58 - $259.14 $776,186 - $861,122	3,323 Added 0.49%	681,536 $166 Million
Q1 2021 Dec 01, 2022	SELL	$221.91 - $258.6 $116 Million - $135 Million	-523,442 Reduced 43.56%	678,213 $169 Million
Q1 2021 Apr 23, 2021	SELL	$221.91 - $258.6 $1.4 Million - $1.63 Million	-6,298 Reduced 0.92%	678,213 $169 Million
Q4 2020 Dec 01, 2022	SELL	$216.38 - $257.67 $112 Million - $133 Million	-517,144 Reduced 43.04%	684,511 $157 Million
Q4 2020 Jan 28, 2021	BUY	$216.38 - $257.67 $1.7 Million - $2.03 Million	7,866 Added 1.16%	684,511 $157 Million
Q3 2020 Oct 29, 2020	SELL	$234.65 - $260.95 $15.9 Million - $17.7 Million	-67,937 Reduced 9.12%	676,645 $172 Million
Q2 2020 Jul 20, 2020	BUY	$197.81 - $242.74 $58.3 Million - $71.5 Million	294,637 Added 65.48%	744,582 $176 Million
Q1 2020 Apr 30, 2020	SELL	$182.24 - $241.7 $4.1 Million - $5.44 Million	-22,506 Reduced 4.76%	449,945 $91.2 Million
Q4 2019 Feb 06, 2020	BUY	$189.21 - $243.2 $8.17 Million - $10.5 Million	43,172 Added 10.06%	472,451 $114 Million
Q3 2019 Oct 17, 2019	BUY	$174.11 - $208.62 $5.17 Million - $6.19 Million	29,680 Added 7.43%	429,279 $83.1 Million
Q2 2019 Jul 19, 2019	SELL	$166.7 - $195.41 $658,465 - $771,869	-3,950 Reduced 0.98%	399,599 $73.6 Million
Q1 2019 May 02, 2019	BUY	$180.87 - $203.88 $11.7 Million - $13.1 Million	64,435 Added 19.0%	403,549 $76.7 Million
Q4 2018 Feb 08, 2019	BUY	$178.4 - $208.25 $3.19 Million - $3.72 Million	17,871 Added 5.56%	339,114 $65.9 Million
Q3 2018 Oct 31, 2018	BUY	$185.29 - $208.89 $105,059 - $118,440	567 Added 0.18%	321,243 $66.6 Million
Q3 2018 Oct 25, 2018	BUY	$185.29 - $208.89 $7.57 Million - $8.54 Million	40,867 Added 14.61%	320,676 $66.5 Million
Q2 2018 Aug 03, 2018	BUY	$166.05 - $186.51 $5.4 Million - $6.06 Million	32,510 Added 13.15%	279,809 $51.7 Million
Q1 2018 May 07, 2018	BUY	$169.43 - $198.0 $15.8 Million - $18.5 Million	93,518 Added 60.81%	247,299 $42.2 Million
Q4 2017 Jan 25, 2018	BUY	$168.79 - $188.59 $16.4 Million - $18.3 Million	97,224 Added 171.9%	153,781 $26.7 Million
Q3 2017 Oct 17, 2017	BUY	$167.29 - $191.0 $248,091 - $283,253	1,483 Added 2.69%	56,557 $10.5 Million
Q2 2017 Aug 08, 2017	SELL	N/A	-308,028 Reduced 84.83%	55,074 $9.48 Million
Q1 2017 Jan 19, 2021	BUY	N/A	363,102	363,102 $59.6 Million

Others Institutions Holding AMGN

# of Institutions

3,279

Shares Held

441M

Call Options Held

6.15M

Put Options Held

7.28M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $161B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Robeco Institutional Asset Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Robeco Institutional Asset Management B.V. with notifications on news.

Account

Robeco Institutional Asset Management B.V. Amgen Inc Transaction History